<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189032</url>
  </required_header>
  <id_info>
    <org_study_id>00890404</org_study_id>
    <nct_id>NCT01189032</nct_id>
  </id_info>
  <brief_title>Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</brief_title>
  <official_title>Dose-Response Study of DE-089 Ophthalmic Solution in Patients With Dry Eye -Late Phase II Confirmatory Study-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      Dose response related to efficacy and safety of DE-089 ophthalmic solution are examined in
      patients with dry eye, using a multicenter, randomized, double-blind, parallel group
      comparison study, and the optimal concentration is determined.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Mean Change in Fluorescein Staining Score From Baseline</measure>
    <time_frame>Baseline and 4-week (discontinued(LOCF))</time_frame>
    <description>Fluorescein staining was scored according to the protocol by Shimmura et al. The cornea was divided into 3 equal zones: upper, middle, and lower. Each zone had a staining score ranging between 0 and 3 points, with minimum and maximum total staining scores ranging between 0 and 9 points. 0 is better.
The degree of staining with Fluorescein dyes was scored as follows: 0 = no staining, 1= staining of less than half of the area, 2= staining of more than half of the area, 3= staining in the whole area.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>High concentration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low concentration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-089 ophthalmic solution</intervention_name>
    <arm_group_label>High concentration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-089 ophthalmic solution</intervention_name>
    <arm_group_label>Low concentration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ophthalmic solution</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Those who show:

               -  Keratoconjunctival disorder confirmed with vital dye staining

               -  Abnormal Schirmer score results

        Exclusion Criteria:

          -  Eye disease that needs therapy other than that for dry eye

          -  Those who need to wear contact lenses during the clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Santen study sites</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <results_first_submitted>May 23, 2014</results_first_submitted>
  <results_first_submitted_qc>July 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2014</results_first_posted>
  <last_update_submitted>August 8, 2014</last_update_submitted>
  <last_update_submitted_qc>August 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Excluded (n=34)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo ophthalmic solution</description>
        </group>
        <group group_id="P2">
          <title>Low Concentration</title>
          <description>1% DE-089 ophthalmic solution</description>
        </group>
        <group group_id="P3">
          <title>High Concentration</title>
          <description>3% DE-089 ophthalmic solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo ophthalmic solution</description>
        </group>
        <group group_id="B2">
          <title>Low Concentration</title>
          <description>1% DE-089 ophthalmic solution</description>
        </group>
        <group group_id="B3">
          <title>High Concentration</title>
          <description>3% DE-089 ophthalmic solution</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="96"/>
            <count group_id="B4" value="286"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="17.3"/>
                    <measurement group_id="B2" value="57.9" spread="16.3"/>
                    <measurement group_id="B3" value="56.4" spread="17.8"/>
                    <measurement group_id="B4" value="56.6" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Fluorescein Staining Score From Baseline</title>
        <description>Fluorescein staining was scored according to the protocol by Shimmura et al. The cornea was divided into 3 equal zones: upper, middle, and lower. Each zone had a staining score ranging between 0 and 3 points, with minimum and maximum total staining scores ranging between 0 and 9 points. 0 is better.
The degree of staining with Fluorescein dyes was scored as follows: 0 = no staining, 1= staining of less than half of the area, 2= staining of more than half of the area, 3= staining in the whole area.</description>
        <time_frame>Baseline and 4-week (discontinued(LOCF))</time_frame>
        <population>Efficacy analysis was performed per protocol set (PPS). Excluded cases were 7 subjects (3 subjects in 3% group, 3 subjects in 1% group, and 1 subject in Placebo group).
The reason of exclusion: used the prohibited concomitant drug, dosing period shortage, number of doses non-compliance, or had no available efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo ophthalmic solution</description>
          </group>
          <group group_id="O2">
            <title>Low Concentration</title>
            <description>1% DE-089 ophthalmic solution</description>
          </group>
          <group group_id="O3">
            <title>High Concentration</title>
            <description>3% DE-089 ophthalmic solution</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Fluorescein Staining Score From Baseline</title>
          <description>Fluorescein staining was scored according to the protocol by Shimmura et al. The cornea was divided into 3 equal zones: upper, middle, and lower. Each zone had a staining score ranging between 0 and 3 points, with minimum and maximum total staining scores ranging between 0 and 9 points. 0 is better.
The degree of staining with Fluorescein dyes was scored as follows: 0 = no staining, 1= staining of less than half of the area, 2= staining of more than half of the area, 3= staining in the whole area.</description>
          <population>Efficacy analysis was performed per protocol set (PPS). Excluded cases were 7 subjects (3 subjects in 3% group, 3 subjects in 1% group, and 1 subject in Placebo group).
The reason of exclusion: used the prohibited concomitant drug, dosing period shortage, number of doses non-compliance, or had no available efficacy data.</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="1.33"/>
                    <measurement group_id="O2" value="-1.34" spread="1.43"/>
                    <measurement group_id="O3" value="-1.55" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>It’s the p-value of linear trend. It’s adjusted for multiplicity.</p_value_desc>
            <method>maximum contrast method</method>
            <method_desc>To confirm dose-response relation, two contrasts were provided; linear trend (-1, 0, 1), and saturated at 1% DE-089 ophthalmic solution (-2, 1, 1).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>It’s the p-value of Saturated at 1% DE–089. It’s adjusted for multiplicity.</p_value_desc>
            <method>maximum contrast method</method>
            <method_desc>To confirm dose-response relation, two contrasts were provided; linear trend (-1, 0, 1), and saturated at 1% DE-089 ophthalmic solution (-2, 1, 1).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo ophthalmic solution</description>
        </group>
        <group group_id="E2">
          <title>Low Concentration</title>
          <description>1% DE-089 ophthalmic solution</description>
        </group>
        <group group_id="E3">
          <title>High Concentration</title>
          <description>3% DE-089 ophthalmic solution</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/J (8.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <description>There was a serious adverse event in 3% DE-089 ophthalmic solution group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA/J (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>General Manager of Clinical Development Group</name_or_title>
      <organization>Santen Pharmaceutical Co., Ltd.</organization>
      <phone>+81-6-4802-9341</phone>
      <email>clinical@santen.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

